Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

DCP2 (Decapping mRNA 2) Antibody [PCRP-DCP2-1D6]

In Stock
HuProt Validated
Catalog Number Formulation Size Price
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab with BSA and Azide at 200ug/ml
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol
Flow Cytometry (Flow)
1-2ug/million cells
Immunofluorescence (IF)


The major pathway of eukaryotic mRNA decay involves deadenylation-dependent decapping followed by 5' to 3'exonucleolytic degradation. Human decapping enzyme 2 (hDcp2) is an mRNA decapping enzyme which contains intrinsic decapping activity. In nonsense-mediated decay, the human decapping complex, made up of hDcp1 and hDcp2, may be recruited to mRNAs containing premature termination codons by nonsense-mediated decay factor (Upf) proteins. The decapping activator complex (Lsm1p-7p) is also involved in the recruitment of the decapping complex, indicated by data showing that Lsm1p-7p enhances the co-immunoprecipitation of the complex with mRNA. Dcp2 specifically hydrolyzes methylated capped RNA to release m7GDP, thereby aiding in mRNA degradation. Both Dcp1 and Dcp2 co-localize in the cytoplasm, which is consistent with their role in mRNA decay

Product Properties & Targets

Antibody Type
Species Reactivity
Isotype / Light Chain
IgG2a /
Cellular Localization
Cytoplasm, Nucleus, P-body
Gene Name
Positive Control
Daudi or Jurkatcells., MCF7
Recombinant full-length human DCP2protein
Alternate Names
m7GpppN-mRNA hydrolase, Nucleoside diphosphate-linked moiety X motif 20, mRNA-decapping enzyme 2, DCP2 decapping enzyme homolog (S. cerevisiae); DFLJ33245; hDpc; m7GpppN-mRNA hydrolase; mRNA decapping enzyme 2; nudix (nucleoside diphosphate linked moiety X)-type motif 20 (NUDT20)

Database Links

Entrez Gene ID

Additional Information

Chromosome Location
Mol. Weight of Antigen


  • Decapping metalloenzyme that catalyzes the cleavage of the cap structure on mRNAs (PubMed:12417715, PubMed:12218187, PubMed:12923261, PubMed:21070968, PubMed:28002401, PubMed:31875550). Removes the 7-methyl guanine cap structure from mRNA molecules, yielding a 5'-phosphorylated mRNA fragment and 7m-GDP (PubMed:12486012, PubMed:12923261, PubMed:21070968, PubMed:28002401, PubMed:31875550). Necessary for the degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay (PubMed:14527413). Plays a role in replication-dependent histone mRNA degradation (PubMed:18172165). Has higher activity towards mRNAs that lack a poly(A) tail (PubMed:21070968). Has no activity towards a cap structure lacking an RNA moiety (PubMed:21070968). The presence of a N(6)-methyladenosine methylation at the second transcribed position of mRNAs (N(6),2'-O-dimethyladenosine cap; m6A(m)) provides resistance to DCP2-mediated decapping (PubMed:28002401). Blocks autophagy in nutrient-rich conditions by repressing the expression of ATG-related genes through degradation of their transcripts (PubMed:26098573).

Key References

  • Wang, Z., et al. 2002. Proc. Natl. Acad. Sci. USA 99: 12663-12668.

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “DCP2 (Decapping mRNA 2) Antibody”

Your email address will not be published. Required fields are marked *


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.